Approved under BLA , this biosimilar offers flexible dosing schedules for various patient needs: Adult CKD : 50 to 100 units/kg 3 times weekly. Pediatric CKD : 50 units/kg 3 times weekly.
: A popular Explorer Forum thread (ID 125545) regarding manual transfer case conversions. 125545
Increased competition in the biologics space continues to drive down healthcare costs while maintaining high standards for patient safety. Approved under BLA , this biosimilar offers flexible
The number most commonly refers to BLA 125545 , an FDA Biologics License Application for Retacrit (epoetin alfa-epbx) , which is a biosimilar to Epogen and Procrit used to treat anemia. Increased competition in the biologics space continues to
: Intravenous or subcutaneous, with IV recommended for hemodialysis patients.
: Supported for both adult and pediatric patients.
: Demonstrated similar pharmacodynamic characteristics and toxicity profiles to the reference product.